摘要
[目的]探讨慢性乙肝、原发性肝癌患者HBVx-DNA表达水平及其临床意义。[方法]用聚合酶链反应对157例慢性乙肝及原发性肝癌患者血清和外周血单个核细胞(PBMC)中HBVx-DNA进行检测。[结果]慢性乙肝、原发性肝癌患者HBVx-DNA总阳性率分别为18.5%(25/135)和63.6%(14/22),两者相比差异有显著性(P﹤0.01)。慢性乙肝及原发性肝癌患者血清和PBMC中HBVx-DNA阳性率分别为11.9%(16/135)、6.7%(9/135)和40.9%(9/22)、22.7%(5/22)。两者相比差异有显著性(P﹤0.01和P﹤0.05)。其中慢性乙肝轻度、慢性乙肝中度、慢性乙肝重度、肝炎后肝硬化患者血清内HBVx-DNA阳性率分别为0%、20.8%(5/24)、17.9%(5/28)、17.1%(6/35),相互比较差异有显著性(P﹤0.01)。慢性乙肝轻度、慢性乙肝中度、慢性乙肝重度、肝炎后肝硬化患者PBMC内HBVx-DNA阳性率分别为0%、8.3%(2/24)、10.7%(3/28)、11.4%(4/35),相互比较差异无显著性(P﹥0.05)。HBeAg(+)组HBVx-DNA总阳性率为30.1%(31/103),与HBeAg(-)组相比,差异有显著性(P﹤0.05)。其中HBeAg(+)组和HBeAg(-)组血清HBVx-DNA阳性率为20.4%(21/103)和7.4%(4/54),差异有显著性(P﹤0.05);HBeAg(+)组和HBeAg(-)组PBMC内HBVx-DNA阳性率为9.7%(10/103)和7.4%(4/54),差异无显著性(P﹥0.05)。AFP(+)组患者HBVx-DNA阳性率为63.6%(14/22),与AFP(-)组患者相比,差异有显著性(P﹤0.01)。[结论]原发性肝癌患者血清和PBMC内HBVx-DNA表达水平均较高,HBVx-DNA与宿主细胞整合可能是导致原发性肝癌发生的重要原因。慢性乙肝患者体内有HBVx-DNA存在,以慢性乙肝中度、重度及肝硬化患者多见,应警惕有诱发原发性肝癌的可能。AFP与HBVx-DNA表达水平具有高度相关性,HBVx-DNA检测对原发性肝癌早期发现和辅助诊断具有重要意义。
[Objective]To study the expression level of HBVx-DNA in serum and peripheral blood mononuclear cells（PBMC）of the patients with chronic hepatitis B and primary hepatoma and its clinical significance.[Methods]The expression levels of HBVx-DNA in serum and PBMC of 157 patients with chronic hepatitis B and primary hepatoma were detected by polymerase chain reaction（PCR）.[Results]The total positive rates of HBVx-DNA in serum and PBMC of the patients with chronic hepatitis B and primary hepatoma were 18.5%（25/135）and 63.6%（14/22）respectively,and there was significant difference between the two（P﹤0.01）.The respective positive rate of HBVx-DNA in serum and PBMC of chronic hepatitis patients and primary hepatoma patients were 11.9%（16/135）,6.7%（9/135）and 40.9%（9/22）,22.7 %（5/22）,and there was significant difference in the two positive rates between the two groups（P﹤0.01 and P﹤0.05）.The positive rates of serum HBVx-DNA of light,moderate,severe chronic hepatitis B patients and posthepatitic cirrhosis patients were 0%,20.8%（5/24）,17.9%（5/28）and 17.1%（6/35）respectively,and there was obvious difference among them（P﹤0.01）.The positive rates of HBVx-DNA in PBMC of light,moderate,severe chronic hepatitis B patients and posthepatitic cirrhosis patients were 0%,8.3%（2/24）,10.7%（3/28）and 11.4%（4/35）respectively,but there was no significant difference among them（P﹥0.05）.The total positive rate of HBVx-DNA in patients with HBeAg（＋）was 30.1%（31/103）,which was significantly higher than that in patients with HBeAg（-）（P﹤0.05）.The positive rates of serum HBVx-DNA of patients with HBeAg（＋）and HBeAg（-）were 20.4%（21/103）and 7.4%（4/54）,respectively,and the two were significantly different（P﹤0.05）.The positive rates of HBVx-DNA in PBMC of patients with HBeAg（＋）and HBeAg（-）were 9.7%（10/103）and 7.4%（4/54）,respectively,but there was no significant difference between the two（P﹥0.05）.The positive rate of HBVx-DNA in patients with AFP（＋）was 63.6%（14/22）,which was significantly higher than that in patients with AFP（-）（P﹤0.01）.[Conclusions]The expression levels of HBVx-DNA in serum and PBMC of primary hepatoma patients are higher.HBVx-DNA integrated with chromosome of host cells may be the main reason for primary hepatoma.HBVx-DNA can be existent in chronic hepatitis B patients,and is more common in moderate and severe chronic hepatitis patients and cirrhosis patients;if so,the possibility of primary hepatoma should be treasured.There is high correlation between the level of AFP and that of HBVx-DNA.Detection of HBVx-DNA is of great clinical significance in early discovery and auxiliary diagnosis of primary hepatoma.
出处
《现代预防医学》
CAS
北大核心
2007年第22期4217-4219,共3页
Modern Preventive Medicine
基金
安徽省教育厅自然科学基金项目(2003uj027zd)
